TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05283226: Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who

Sponsor: NATCO Pharma Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 21 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,478,400

Unlock Full NCT05283226 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05283226 Rescue Dossier →